Trial · NCT03213457
Results by group36
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 36
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Co-Primary Endpoint: Percentage of Participants With a Response for Dysmenorrhea (DYS) at Months 6 and 12 Based on Daily Assessment | Placebo | Month 6 | 23.7 | 95% Confidence Interval 17.64 to 29.73 | percentage of participants |
| Co-Primary Endpoint: Percentage of Participants With a Response for Dysmenorrhea (DYS) at Months 6 and 12 Based on Daily Assessment | Elagolix + E2/NETA | Month 6 | 62.8 | 95% Confidence Interval 57.93 to 67.60 | percentage of participants |
| Co-Primary Endpoint: Percentage of Participants With a Response for Dysmenorrhea (DYS) at Months 6 and 12 Based on Daily Assessment | Placebo | Month 12 | 29.1 | 95% Confidence Interval 22.62 to 35.58 | percentage of participants |
| Co-Primary Endpoint: Percentage of Participants With a Response for Dysmenorrhea (DYS) at Months 6 and 12 Based on Daily Assessment | Elagolix + E2/NETA | Month 12 | 63.8 | 95% Confidence Interval 58.97 to 68.69 | percentage of participants |
| Co-Primary Endpoint: Percentage of Participants With a Response for Non-menstrual Pelvic Pain (NMPP) at Months 6 and 12 Based on Daily Assessment | Placebo | Month 6 | 36.8 | 95% Confidence Interval 29.98 to 43.70 | percentage of participants |
| Co-Primary Endpoint: Percentage of Participants With a Response for Non-menstrual Pelvic Pain (NMPP) at Months 6 and 12 Based on Daily Assessment | Elagolix + E2/NETA | Month 6 | 51.3 | 95% Confidence Interval 46.30 to 56.30 | percentage of participants |
| Co-Primary Endpoint: Percentage of Participants With a Response for Non-menstrual Pelvic Pain (NMPP) at Months 6 and 12 Based on Daily Assessment | Placebo | Month 12 | 42.3 | 95% Confidence Interval 35.28 to 49.37 | percentage of participants |
| Co-Primary Endpoint: Percentage of Participants With a Response for Non-menstrual Pelvic Pain (NMPP) at Months 6 and 12 Based on Daily Assessment | Elagolix + E2/NETA | Month 12 | 54.3 | 95% Confidence Interval 49.22 to 59.29 | percentage of participants |
| Change From Baseline in DYS at Month 12 Based on Daily Assessment | Placebo | -0.73 | Standard Error 0.077 | score on a scale | |
| Change From Baseline in DYS at Month 12 Based on Daily Assessment | Elagolix + E2/NETA | -1.73 | Standard Error 0.055 | score on a scale | |
| Change From Baseline in DYS at Month 6 Based on Daily Assessment | Placebo | -0.62 | Standard Error 0.072 | score on a scale | |
| Change From Baseline in DYS at Month 6 Based on Daily Assessment | Elagolix + E2/NETA | -1.64 | Standard Error 0.050 | score on a scale | |
| Change From Baseline in DYS at Month 3 Based on Daily Assessment | Placebo | -0.56 | Standard Error 0.069 | score on a scale | |
| Change From Baseline in DYS at Month 3 Based on Daily Assessment | Elagolix + E2/NETA | -1.54 | Standard Error 0.049 | score on a scale | |
| Change From Baseline in Non-menstrual Pelvic Pain (NMPP) at Month 12 Based on Daily Assessment | Placebo | -0.64 | Standard Error 0.060 | score on a scale | |
| Change From Baseline in Non-menstrual Pelvic Pain (NMPP) at Month 12 Based on Daily Assessment | Elagolix + E2/NETA | -0.86 | Standard Error 0.042 | score on a scale | |
| Change From Baseline in NMPP at Month 6 Based on Daily Assessment | Placebo | -0.57 | Standard Error 0.051 | score on a scale | |
| Change From Baseline in NMPP at Month 6 Based on Daily Assessment | Elagolix + E2/NETA | -0.78 | Standard Error 0.036 | score on a scale | |
| Change From Baseline in NMPP at Month 3 Based on Daily Assessment | Placebo | -0.49 | Standard Error 0.046 | score on a scale | |
| Change From Baseline in NMPP at Month 3 Based on Daily Assessment | Elagolix + E2/NETA | -0.65 | Standard Error 0.032 | score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03213457/results